Ergoteles’s RAPT Therapeutics RAPT Stock Holding History

Ergoteles’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,575	Closed	-$230K	–	1907
2022 Q2	$230K	Buy	+1,575	New	+$210K	0.01%	1249

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ergoteles's RAPT Position: Q3 2022 in Review

Ergoteles sold out of RAPT Therapeutics (RAPT) in Q3 2022, closing a stake of 1,575 shares — an estimated $230K sold.

Ergoteles first reported a position in RAPT in Q2 2022 and held it in 1 quarter. The position peaked at $230K in Q2 2022. 98 funds tracked by Wall St. Rank hold RAPT as of Q3 2022.

Ergoteles reported no remaining RAPT Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 1,575 RAPT Therapeutics shares in Q3 2022, an estimated $230K.
Ergoteles first reported a position in RAPT Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's RAPT Therapeutics position peaked at $230K in Q2 2022.
98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.